The Valley Desk

NCT05227703 · Interventional trial

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Overall registry status Completed

Phase 2

Conditions Schizophrenia

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov